Trial reportTranslational vision science & technology2025
Influence of Cannabidiol Use on Visual Function and Optical Quality: A Randomized Controlled Trial.
Trial report in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To study the influence of different concentrations of vaporized cannabidiol (CBD; 0%, 15%, and 30%) on visual function and optical quality. Methods: A randomized, crossover, double-blind, placebo-controlled, experimental study was conducted. A total of 30 participants with a mean age of 26.0 ± 6.3 years completed the study. Placebo (0 mg of CBD), 15% (16 mg of CBD), and 30% (32 mg of CBD) concentrations of CBD were employed. Visual function was evaluated through various tests, including pupil size, static and dynamic visual acuity, contrast sensitivity, dot motion detection, visual disturbance index (VDI), and stereoacuity. Optical quality was assessed by log(s), modulation transfer function (MTF) cutoff, objective scattering index (OSI), and Strehl ratio. Self-perceived visual effects were also recorded. Results: There was no significant impairment of static and dynamic visual acuity. Contrast sensitivity was unaffected by CBD use. Mean dot motion detection showed no differences among the three concentrations. In optical quality, none of the parameters worsened under CBD use. No changes were observed for the VDI. In addition, no deterioration was observed for stereoacuity at distance or near. No changes in pupil size were found after CBD consumption. Conclusions: This non-psychotropic CBD did not appear to adversely affect vision and seems to be a safe substance in the short term at the concentrations assessed. Translational Relevance: The use of this cannabinoid would not be dangerous for tasks that rely heavily on vision. This study could be useful and helpful for evidence-based decision-making for public health policy on its use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.